Posted by: midastouch017 In reply to: None Date:7/11/2007 8:06:58 AM Post #of 2102 Former CEO of US Bioscience, Inc., Dr. Philip J. Schein, Joins Pluristem Business Advisory Board Wednesday July 11, 8:00 am ET NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS - News; DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that Dr. Philip J. Schein has joined its Strategic Business Advisory board, headed by Frank Carlucci. Dr. Schein, the Founder of US Bioscience, took three new therapies for cancer and HIV through the development and regulatory approval processes, and established marketing alliances in the US and throughout the world. His company was acquired by Medimmune for $450 million in 1995. Medimmune has recently been acquired by AstraZeneca for approximately $16 Billion. Dr. Schein is the author of over 350 articles and texts in the fields of clinical cancer research and drug development. He is the holder of 11 patents and the recipient of numerous scientific and medical awards. President Clinton appointed Dr. Schein to the National Cancer Advisory Board. He also served as President of the American Society of Clinical Oncology, and has chaired the Food and Drug Administration's Oncologic Drugs Advisory Committee, where he received the Harvey W. Wiley Medal. Dr. Schein said, "Pluristem's technology has the potential to be very beneficial in bone-marrow transplantation, Parkinson's Disease and heart disease. I want to be part of that." "We are honored to have Dr. Schein join our board," commented Zami Aberman, Chairman and CEO, "he has built a significant biotechnology company before, and his experience will be invaluable to Pluristem as we execute our ambitious growth plan." About Pluristem: Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB). Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market. Pluristem has offices and is incorporated in the USA with research and manufacturing facilities in Israel. www.pluristem.com http://biz.yahoo.com/bw/070711/20070711005478.html?.v=1